Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo aims to shrink lung tumors before surgery in targeted therapy trial

NCT ID NCT07182708

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tests whether giving a high dose of firmonertinib (a targeted pill) plus bevacizumab (an IV drug that blocks blood vessel growth) before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). About 62 adults whose cancer can be surgically removed will receive the combination for several weeks, then undergo surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue. This is not a cure, as ongoing monitoring and possible further treatment are expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EGFR ACTIVATING MUTATION EGFR ACTIVATING MUTATION NSCLC (NON-SMALL CELL LUNG CANCER) RESECTABLE LUNG NON-SMALL CELL CARCINOMA